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Pharmacists are becoming more tired as the workload of 
dispensing and therapy grows, and the demand-supply 
goal becomes more difficult. This encourages more 
pharmacists, who are often active in clinical pharmacy 
within the healthcare system1. The clinical pharmacy's 
facilities are the primary reason for its increased demand. 
As a result, it has become an essential and important 
component of the healthcare system, which is critical in 
this multidisciplinary setting2. 
Pharmacists play a critical role in patient education and 
encouragement, as well as advising and engaging with 
prescribers3. Clinical pharmacists bridge the gap between 
doctors and their patients by having a thorough 
understanding of medications and treatment plans. As a 
result, clinical pharmacists and doctors will work 
together to build a strong pillar for society by providing 
high-quality patient care4. The presence of a clinical 
pharmacist in and around healthcare is critical to the 
pharmacy field's growth5. 
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Drug-related problems (DRPs) had often been a concern in the system 
that needed to be detected, avoided, and addressed as soon as 
possible. The need for a clinical pharmacist becomes even more 
important. He is the one who can not only share the load but also be 
an important part of the system by providing required advice. They 
fill out the patient's pharmacotherapy reporting form and notify the 
medical team's head off any drug-related issues. General practitioners 
register severe adverse drug reactions (ADRs) yearly. As a result of all 
of this, a clinical pharmacist working in and around the healthcare 
system is expected to advance the pharmacy industry. Its therapy and 
drugs can improve one's health quality of life by curing, preventing, 
or diagnosing a disease, sign, or symptom. The sideshows, on the other 
hand, do much harm. Because of the services they offer, clinical 
pharmacy has grown in popularity. To determine the overall effect 
and benefits of the emergency department (ED) clinical pharmacist, a 
systematic review of clinical practice and patient outcomes will be 
needed. A clinical pharmacist's anatomy, toxicology, pharmacology, 
and medicinal chemistry expertise significantly improves a patient's 
therapy enforcement. It is now important to examine the failure points 
of healthcare systems as well as the individuals involved. 
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It is assumed that a professional person who can treat 
patients is titled a doctor, physician, clinician, medical 
practitioner, and others in the present scenario. These 
people support the medical system and improve the 
healthcare departments as they have achieved a degree 
in medical or allied health6. A system like this is critical for 
any country's growth. These individuals are regarded as 
the best because they lead a healthcare system that is 
constantly in need of perfection and change7. Thus, the 
necessity for a clinical pharmacist also becomes crucial. 
They are the ones who not only share the load but often 
be a responsible part of the system for their advice which 
is needed to be a cure, treats or even save a life1. This 
review will discuss several things related to the role of 
clinical pharmacists in patient-oriented pharmaceutical 
services, including various activities undertaken, such as 
medication reviews, counseling, therapeutic drug 
monitoring, and adverse drug reactions that may occur 
due to negligence in pharmaceutical care, as well as the 
expected outcomes of patient-centered clinical services. 
 
DRUG-RELATED PROBLEMS 
Drug-related problems (DRPs) have often been a 
systemic concern that must be recognized, avoided, and 
handled as soon as possible. Any cure for the problem 
isn't new8. Different terms are proposed; for instance, 
'drug-treatment issue' is regularly utilized as well, and 
this term was presented by Cipolle et al9. Krska10 
proposed the term 'Drug Care Issue' in 2002. This is 
regularly utilized in the UK. Pharmacotherapy 
disappointment compares to negative clinical results 
coming about because of the usage or the absence of 
meds11. 
Various reports have come forward which enlists "drug-
induced problem" since many efforts have been put 
forward to optimize the rational usage of the drug and 
medical preparations12. In such cases, a variety of factors 
can play a crucial role, like social pressure on the 
physician, the law and system of healthcare services, and 
the marketing strategies of pharmaceuticals, plus the 
patient itself play an essential role in this system. 
Polypharmacy and increased drugs use are two factors 
that contribute to problems that defy 
pharmacotherapeutic concepts. Such issues are then 
categorized as DRPs13,14. Niriayo et al.15 describe the 
points included in the DRPs based on Cipolle's method 
as presented in Table I. 





1. There are no valid medical indications for drug 
therapy at that time 
2. Several medicinal products are used for 
conditions sufficient with single drug therapy 
3. Medical conditions are more appropriately 
treated with non-drug therapy 
4. Drug therapy is used to treat the side effects 






1. Medical conditions requiring initiation of drug 
therapy 
2. Preventive drug therapy is needed to reduce 
the risk of developing new medical conditions 
3. Medical conditions require additional drug 





1. The least effective drugs are used while the 
most effective drugs are available 
2. Drugs are used to treat medical problems that 
are resistant to most treatments. 
3. The medicinal products used are ineffective for 
the medical condition that is being treated 
Dosage too 
high 
1. The drug dose is too high 
2. The frequency of drug doses was too short 
3. Drug interactions that can cause toxic reactions 
to medicinal products. 
4. The drug dose was given too quickly 
Dosage too 
low 
1. The drug dosage is insufficient to achieve the 
desired effect. 
2. Interactions between drugs that can minimize 
the number of active drugs available 
3. The length of drug therapy is insufficient. 




1. The medicine has an unfavorable side effect 
that is not dose-related. 
2. An unfavorable reaction is caused by a drug 
interaction that is not dose-related. 
3. The medication causes an allergic reaction 
4. The drug is contraindicated due to risk factors 




1. Inability to comprehend the instructions 
2. Choosing not to take the drug 
3. Negligence 
4. Inability to properly take the drug on its own 
5. Issues related to affordability and availability 
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MEDICATION ERROR 
Many therapies and medications have been involved 
that cure, prevent, or diagnose a disease, sign, or 
symptom to enhance the standard of life in health. 
However, improper usage of those drugs can cause 
severe damage by creating new adverse situations, be it 
morbidity or mortality16. From 1.5 to 35%, errors related 
to medication were reported to the patients under 
hospitalization, and DRPs were seen to be common. 
Around 6.5% of morbidity and mortality rates of these 
errors were considered liable for costs of hospitalized 
persons, and It was discovered that two-thirds of these 
incidents could have been avoided17. To reduce the 
potential risk of these errors, pharmaceutical care 
provided by clinical pharmacists in the hospital setting 
allows multiple layers of patient protection18. 
Although few reports have uttered the improvement in 
medication error management by involving clinical 
pharmacists, there is insufficient knowledge in some of 
the developing countries19, such as Iran. A clinical drug 
store residency program was begun in the year 1994 in 
Iran, and till now, almost 100 clinical drug specialists got 
earned their diplomas. A large portion of them was the 
academic staff and was occupied with the clinical 
treatment group in the instructing clinics. Drug audit by 
the drug specialists in the emergency clinic setting is in 
advancement because of the association of clinical drug 
specialists on the medical care group in the irresistible 
sicknesses ward of Imam Hospital, Tehran, Iran20. 
Pharmacists are expected to review medical charts as part 
of their normal duties. They reported pharmacotherapy 
monitoring, and all the reports of drug problems were 
submitted to the head of the medical team21. To optimize 
the result in a complex situation, it must possess an 
emergency system, diagnostic procedure, sufficient 
clinical therapy, availability of antidotes, supportive 
services, and the best knowledge for managing the 
clinical cases. A multidisciplinary team gives more 
results than a monodisciplinary way22,23. Hospital 
pharmacy and pharmacists have got a synonymous role 
here. 
 
CLINICAL PHARMACY AT EMERGENCY 
DEPARTMENT 
For assessing the efficacy and safety of a particular 
medication combination of the knowledge of 
pharmaceutics, pharmacokinetics, pharmacodynamics, 
and therapeutic drug monitoring (TDM) is required in 
various clinical settings24. The development of modern 
analytical techniques has made the determination of 
pharmacokinetic parameters easier by measuring the 
concentration of drugs in the blood. Such parameters 
give necessary information about a medicament by 
assessing it clinically25. As a result, TDM is a method that 
aids a medical practitioner in providing a patient with a 
safe and successful care. Next, good monitoring from 
medical practitioner can confirm plasma-drug 
concentration above or below in the therapeutic range26. 
Adverse drug reactions (ADRs) are life-threatening 
situations. This imparts a negative effect on the standard 
of life and strives significant expenses on the healthcare 
systems27,28. In the United States, the fourth cause of death 
rate is ADRs29. The death rates are much higher due to 
medication errors and ADRs than the death caused by 
any highway accident, cancers, or AIDS, stated by recent 
data30. Moreover, it has been reported that around 7% of 
hospitalizations are the results of ADRs29,31,32. 
 
THE ROLE OF CLINICAL PHARMACISTS 
In the patient-oriented era, the clinical pharmacist is 
defined as a discipline that focuses on improving the 
efficacy and rationality of drugs and minimizing drug 
toxicity in patients based on pharmaceutical care. In 
general, patient-oriented clinical pharmacists' role 
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includes medication reviews, providing counseling, 
therapeutic drug monitoring, and ADRs monitoring33,34, 
as illustrated in Figure 1. In addition, clinical pharmacists 
also have other roles, such as identifying drug-related 
problems, promoting and recommending medication 
fulfillment, reviewing treatment data and medical 
history, examining medication errors including drug 
prescriptions, dispensing errors and drug 
administration, identifying drug interactions, suggest 
individual dosages, provide patient consultations, and 
more35-39. Clinical pharmacy services are not limited to the 
activities mentioned above, in which clinical pharmacists 
can also carry out an expanded role such as conducting 
complete interviews with patients or their families about 
patient history such as medical, social, allergies, use of 
OTC drugs, dietary supplements, and alternative 
medicine4,40. 
 
Figure 1. The role of the patient-centered clinical pharmacists 
 
MEDICATION REVIEW 
In terms of patient care and safety, medication-related 
errors are quite frequent and are an important factor that 
should be given extra attention. As a result, it is important 
to pay attention to the weak points of healthcare systems 
as well as the patients involved41. Pharmacist 
intervention is useful in promoting proper therapy 
compliance, interviewing patients, reconciling 
prescriptions, and advising patients for proper follow-
up, according to findings from different studies42,43. 
Hence, clinical pharmacists are mandatory to participate 
actively as a member of the healthcare team and teach. 
Their fundamental responsibility is to check on drug 
therapy, review patient(s) medical records, attend ward 
rounds, and educate health care workers about disease 
management pharmacologically and non-
pharmacologically44. These outcomes of the drug therapy 
care given by clinical pharmacists are fresh to the 
hospitals. Infectious diseases may be spread through 
medication errors. The number of errors varies 
depending on the patient's demographics, as well as his 
or her illness and drug background, both past and 
current45. 
Another related research drew attention to drug mistakes 
by putting them in the context of patients' problems46. 
Drug dosing and therapy choice problems can cause 
most errors—reasons for medication errors in a pediatric 
surgical ward may be due to improper dose adjustment 
to that patient47. The qualities of drug blunders during the 
organization period of the medicine use measure were 
contemplated. Out of the relative multitude of 
preeminent basic mistakes should be oversight blunders, 
blunders of the wrong portion of medication, and wrong 
time48.  
The high chance and event of drug mistake could 
likewise be because of paper-based requests in clinical 
history alongside automated enlistment of medicine, 
inaccessibility of the clinical record for drug specialists in 
the medical clinic drug store, tolerant over-burden in a 
showing clinic, and therefore working over-burden of 
doctor and attendants as well as inaccessibility or absence 
of therapy guidelines49-51. The reason for contrasts 
between frequencies of meds blunders is prescription 
blunders, the precision of information assortment 
technique, and revealing framework. Furthermore, the 
degree of polished methodology, individual execution, 
and individual social abilities of the elaborate medical 
services laborers may impact the term and kind of the 
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prescription mistake52. Intercessions of clinical drug 
specialists inside the entire treatment measure, starting 
from apportioning to the organization to the patient, can 
limit the odds of medicine mistakes and be advantageous 
to tolerant care. This accomplishment is simply due to the 
contribution of clinical drug specialists in unique 
prescription ward adjusts and noticing and breaking 
down various strides of drug care53. Thus, the principal 
part of crisis division drug specialists is to lessen possibly 
hurtful medicine mistakes brought about by any factor54. 
For the medicine mistakes, it has been discovered that 
patients more than 50 years of age, male sex, and 
quantities of controlled medications had no huge impacts 
except that non-antitoxin drug classes probably show 
hazard factor identified with a quiet segment or illness 
and treatment55,56. Even though the connection between 
the recurrence of prescription mistakes and quantities of 
regulated medications has not found as a danger factor. 
Medical service workers are included as therapy and 
patient care groups in providing instructions to 
emergency clinics to reduce prescription errors57. 
Horribleness, death rate, and cost of patient consideration 
get influenced by medicine errors. Most of the 
prescription mistakes were distinguished, detailed, and 
introduced in the beginning stage of medication 




It is well recognized that taking an excessive number of 
drugs can lead to a person being admitted to the hospital, 
either directly or indirectly. According to the 
Pharmaceutical Care Network Europe (PCNE), DRPs are 
characterized as an occasion or situation, including drug 
treatment that really or possibly meddles with the ideal 
wellbeing outcomes17. Some DRPs like prescription 
blunders and unfriendly medication responses are truly 
basic on account of hospitalized patients and may cause 
patients some dreariness or mortality59. There are a few 
characterization frameworks for DRPs; some are by 
Strand et al.60, an agreement bunch in Granada, the 
PCNE61, and Apoteket AB (National Corporation of 
Pharmacies in Sweden)62. Drug-related problems can be 
experienced throughout the entire medication process 
and perhaps tell you all the risk factors for adverse drug 
reactions and events. In recent years, drug-induced 
morbidity has often been related to adverse drug 
reactions; still, these occupy a small portion of DRPs63.   
Clinical drug specialists are assigned specialists who can 
co-relate determination, research center qualities, clinical 
history, and solutions with the progressing treatment of 
an individual patient64. Thus, the presence of a clinical 
drug specialist is essential so he can distinguish and 
tackle a few DRPs more effectively than a fake 
framework can, for example, Computerized Physician 
Order Entry frameworks (CPOE) or Clinical Decision 
Support System (CDSS). Many investigations have 
detailed that a clinical drug specialist is crucial, which 
offers better assistance for persistent consideration and 
wellbeing65,66. 
In one study, the contingency of DRPs was correlated 
with age, gender, polypharmacy, and several 
comorbidities. An identical study was done, in which 
correlation of variables like age, gender and 
polypharmacy was established with an increase in 
DRPs67,68. The research was carried out that stresses the 
role in identifying, assessing, and preventing DRPs in 
elderly patients. They also focused on polypharmacy (six 
or more concomitantly) leading to DRPs69. The factors 
leading to DRPs were polypharmacy, comorbidities, and 
patient age reported by a study. As far as age-related 
DRPs are concerned, most patients were in the geriatric 
age group; a maximum number of DRPs were seen in 
this group. Maximum numbers of medicines were 
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prescribed in this group, i.e., approximately an average of 
10 to 15 drugs per patient. The number of DRPs and 
medications prescribed is eventually increased 
depending on the patient's illness or disease, which was 
accompanied by an increase in the age range of 
patients70,71. 
Moreover, this leads to an increase in the age group, 
which shows a rise in the number of comorbid 
conditions, which is the highest amongst the other 
population groups. Multiple comorbid conditions, 
polypharmacy, inadequate knowledge about the disease, 
and others can be the reason behind it. The correlation 
coefficient of age v/s DRPs was 0.13, indicating a positive 
correlation between the two variables72. Chances of DRPs 
increase with the rise in age. With the increase in DRPs, 
age development, comorbid conditions increase, and as a 
result, the number of drugs prescribed increases73. The 
leading cause of DRPs is considered to be polypharmacy. 
Drug-drug interaction is the main reason for a positive 
correlation between the numbers of drugs prescribed 
and DRPs74. 
Maximum of major and significant drug-drug 
interactions was recognized in this age bunch, out of 
which few were intentional\beneficial. Drug-drug 
interactions can lead to a decrease or increase in a drug's 
effect, eventually causing a sub-therapeutic or supra-
therapeutic dose75. Thus, to reduce the occurrence of 
drug-drug interactions, pharmacokinetics and 
pharmacodynamic properties of drugs should be kept in 
mind as DRPs are mostly dependent on chemical as well 
as physical properties of the drug and, as a consequence, 
are often more difficult to influence and prevent76. 
Various methods have been proposed to prevent drug 
interactions and made to work. Firstly, the 
pharmacokinetic properties of each drug are observed. If 
found any discrepancy such as the half-life of the drug is 
not crossed, then the administration timing can be varied 
and changed accordingly77. The following method is to 
provide an alternate therapy plan to a patient. Such 
interactions are notable and are needed to be checked and 
monitored often. For such instances, an alternate therapy 
plan works well by minimizing interactions with 
substituting medications for their counterparts. When 
these plans are carried out and implemented, the 
medication reactions are better presented, and the patient 
receives the best care possible78. 
 
THERAPEUTIC DRUG MONITORING 
Therapeutic drug monitoring is a branch of the clinical 
chemist in which data is determined by a clinician, how a 
patient responds to a specific therapy and the factors that 
influence that response. When a therapy fails due to a 
patient's insufficient reaction, quantitative examination of 
plasma levels will show who is truly following the 
instructions and who is not26. The approach also provides 
data on individual reactions to drug use habits and 
changes in drug usage as a result of the altered 
physiological condition. A critical point of TDM is to seek 
out the dose-response relationship, its affectivity, 
rationale, and others51. This TDM is much acceptable and 
needed for a few categories of drugs when value and 
quality of life are considered. Such a category may be 
noted by public bodies and regulatory agencies for TDM 
to be carried out. The reality of TDM is that it is based on 
estimating drug concentrations in body fluids like saliva, 
plasma, serum, and others79. 
Except for drugs that do not follow the dose-response 
relationship or facts such as individual variations, 
particular variations, or ethnic variations, the TDM is also 
very effective in delivering a beneficial service if the 
medication has a dose-response relationship80. Reporting 
blood concentrations can be of no use or may even make 
treatment more difficult. The TDM assay must be 
performed for both the administered drugs and their 
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metabolite for particular drug groups where the 
metabolite is also active. The use of therapeutically low 
concentrations of drugs in fewer patients than the normal 
dose has been shown to be highly successful81. In a few 
patients, a higher concentration than the normal range of 
serum concentration is needed without causing any 
harmful effects and yielding a satisfactory result. 
However, such circumstances may indicate that higher 
doses are toxic concentrations, causing undesirable 
anxiety and necessitating a dose reduction. One must 
consult the physician and clinical pharmacist to urge a 
better conclusion by approaching a team discussion82,83. 
Therapeutic drug monitoring is the best option required 
for critical conditions and requires emergency support. 
The reports should be made available within a short 
duration to make TDM very effective84. Therapeutic drug 
monitoring can also be helpful for neonates and pregnant 
ladies. During pregnancy, physiological changes are 
expected, like increased renal function, increased cardiac 
output, increased placental blood flow, variations in the 
concentration of plasma proteins, hormonal changes, 
and others85. Since drugs are administered to sustain and 
promote good health and ill conditions throughout 
pregnancy, these drugs may be capable of crossing the 
placental barrier and causing toxic effects on the fetus, 
TDM is needed. This method is also crucial for neonates 
during their treatment, but many issues are also 
observed86. Many medications, for example, must be 
started right away without any prior knowledge of the 
neonate's clinical history. Drugs are appreciated more 
than their adverse effects, such as jaundice, in such 
situations. The issues that can cause some alteration in 
TDM of neonates can be the cluster of samples, correct 
administration of drugs, their response to drugs, the 
presence of drugs in the body that are received through 
the placenta, or the exposure of the body to drugs in the 
fetus. In such cases, the clinical team's combined effort 
will have further advantages and justification87,88.  
The medication level assessment in body fluids must be 
cost-effective in terms of expenses. The expenditure of 
operating a specific test is directed by the summation of 
equipment, personnel, supply, and overall expenditure 
for particular time duration and dividing that amount by 
the number of analytical tests performed in the same 
duration89,90. The overall charges are then calculated by 
multiplying the desired benefit by the expense of the test. 
The use of clinical pharmacokinetics by therapeutic drug 
monitoring services was considered to reduce adverse 
reactions, reduce intensive care unit length of stay, and 
shorter overall hospital care costs26.  
As mentioned earlier, TDM can appear to be of less 
benefit in certain countries, but when special therapies 
are taken into account, it proves to be extremely valuable 
in terms of delivering effective service. When the failure 
of a therapy or harmful effects is considered, this method 
rises as a powerful tool used in the treatment. It 
necessitates the use of pharmaceutical, pharmacokinetic, 
and pharmacodynamic techniques in tandem91. The 
system's proper operation necessitates a simple 
calculation of the drug level in the blood and reference to 
the normal range. It also increases a drug's protection and 
efficacy in a specific person; additionally, it helps identify 
noncompliant patients' problems92. The time of sample 
collection after dose administration, the dosage history, 
the patient's response, and the desired clinical goals all 
play a role in providing patient-centered disease 
management93. 
 
ADVERSE DRUG REACTIONS 
One study found that after education and the 
establishment of Pharmacovigilance Committees in 
hospitals, there was a substantial increase in ADR 
reporting. It is engrossing that despite sending the 
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documents, posters, and pamphlets of the Iranian 
Adverse Drug Reactions Monitoring Center (IADRMC) 
since 2004, the number of ADRs was deficient from 2004 
until 2007. Despite the fact that the author saw a rise in the 
number of ADRs after 2007, an essential aspect of the 
experience was that the frequency of reports was not as 
good as it should have been94,95. 
The lack of awareness of the national center, the absence 
of serious drug reactions, and skepticism about the 
causality relationship between the reaction and 
suspected drug were all stated as major reasons in the 
report96. Pharmacists and nurses were proposed for 
similar reasons. It was stated from the above studies that 
the top cause of ADRs were antibiotics approximately 
45.5%. Moreover, ceftriaxone was the most common 
antibiotic linked to ADRs, with side effects such as rash, 
hives, and anaphylactic shock97. Technically, high levels 
of antibiotic-associated ADRs are frequently linked to 
high drug use, both within and outside the world. More 
than half of all patients who take antibiotics see a doctor, 
and this number rises to 59% for general practitioners98. 
Adverse drug reactions are more reported in nurses as 
compared to physicians and pharmacists. Due to the 
close contact with both the physicians and the patients 
and management of drug administration of those 
patients, it is counted as the leading cause99. Until 2002, 
the nurses in England were not allowed to fill out yellow 
cards. The role of nurses in the pharmacovigilance 
system was demonstrated by relating all previous studies 
and experience100. At least one injectable drug is used in 
45% of prescriptions. By avoiding needless injections, 
such ADRs can be avoided. Since injectables are not often 
needed for successful outcomes, and because of the 
higher costs and serious and immediate adverse 
reactions, oral drugs are likely to be preferred wherever 
possible to minimize the highest risk of injectable 
ADRs101,102. 
CONCLUSION 
Clinical pharmacists play an important role in the crisis 
center, which is continuously evolving. Other medical 
care laborers claim additional time from clinical 
pharmacists to be given to the office to offer fundamental 
types of assistance. Experienced clinical pharmacists can 
assist with calming tension on other staff and give 
compelling patient consideration. Nevertheless, a proper 
investigation of clinical practice and patient results would 
be needed to survey the general effect and advantages. 
Clinical pharmacists are recognized patient 
consideration advantage by working together with 
doctors or wellbeing frameworks. This enables them to 
participate in dynamic treatment exercises as part of the 
patient's care services team, assisting in the rational use of 
drugs for patient safety and improving long-term 
consideration. The executives' findings assume liability 
for threat factors related to treatment and reduce medical 
care expenses based on their level of consideration and 
illness. Therefore, clinical pharmacists are a resource for 
the health care team and patients. 
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